Open Access
Feature Article

Australia’s COVID-19 vaccination program

Open Access
Feature Article

Australia’s COVID-19 vaccination program

Gemma Reynolds, Janine M. Trevillyan

Figures

© alphaspirit.it/shutterstock
© alphaspirit.it/shutterstock
Dr Reynolds is an Infectious Diseases Advanced Trainee in the Department of Infectious Diseases, Austin Health, Melbourne. Dr Trevillyan is Head of Clinical Virology and HIV Services, Department of Infectious Diseases, Austin Health; and Lead in the COVID-19 Vaccination Program for the Austin Hub, Melbourne, Vic.

 

Advertisement

References

1.    Australian Government Department of Health. TGA provisionally approves Pfizer COVID-19 vaccine 2021 [media release]. 25 January 2021. Available online at: https://www.tga.gov.au/node/936166 (accessed April 2021).
2.    Australian Government Department of Health. TGA provisionally approves AstraZeneca’s COVID-19 vaccine [media release]. 16 February 2021. Available online at: https://www.tga.gov.au/node/936567 (accessed April 2021).
3.    Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial [press release]. 28 January 2021. Available online at: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3 (accessed April 2021).
4.    Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020; 383: 2439-2450.
5.    Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396: 479-488.
6.    Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; 383: 2320-2332.
7.    Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-2615.
8.    Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against  SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99-111.
9.  Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial [media release]. 28 January 2021. Available online at: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3 (accessed April 2021).
10.    Australian Technical Advisory Group on Immunisation (ATAGI). Clinical guidance on use of COVID-19 vaccine in Australia in 2021. Version 2.0. 24 February 2021. Available online at: https://www.health.gov.au/sites/default/files/documents/2021/03/covid-19-vaccination-atagi-clinical-guidance-on-covid-19-vaccine-in-australia-in-2021_0.pdf (accessed March 2021).
11.    Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397: 881-891.
12.    Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine 2021; 39: 457.
13.    Pfizer Australia. Australian product information – COMIRNATY (BNT162b2 [mRNA]) COVID-19 vaccine. Revised 12 March 2021. Sydney: Pfizer Australia; 2021.
14.    AstraZeneca. Australian product information. COVID-19 vaccine AstraZeneca (ChAdOx1-S) solution for injection. Revised 26 March 2021. Sydney: AstraZeneca; 2021.
15.    Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people [preprint] 19 Feb 2021. Available online at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789264 (accessed April 2021).
16.    Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England [preprint]. medRxiv 2021; 2021.03.01.21252652. 
17.    CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep 2021; 70: 46-51. 
18.    Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021; 325: 780-781.
19.    Australian Government Department of Health. AstraZeneca ChAdOx1-S COVID-19 vaccine. Update - expert review finds no evidence of increased risk of anaphylaxis [alert]. 19 March 2021. Available online at: https://www.tga.gov.au/alert/astrazeneca-chadox1-s-covid-19-vaccine-0 (accessed April 2021).
20.    Australian Government Department of Health. AstraZeneca ChAdOx1-S COVID-19 vaccine. Update - European and UK reviews find no proven link with blood clots [alert]. 19 March 2021. Available online at: https://www.tga.gov.au/alert/astrazeneca-chadox1-s-covid-19-vaccine (accessed April 2021).
21.    Australian Government Department of Health. ATAGI statement for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions. 25 March 2021. Available online at: https://www.health.gov.au/news/atagi-statement-for-health-care-providers-on-suitability-of-covid-19-vaccination-in-people-with-history-of-clotting-conditions (accessed April 2021).
22.    Australian Government Department of Health. ATAGI statement on COVID-19 vaccination and a reported case of thrombosis. 2 April 2021. Available online at: https://www.health.gov.au/news/atagi-statement-covid-19-vaccination-reported-case-of-thrombosis (accessed April 2021).
23.    Australian Government Department of Health. Updated ATAGI statement for healthcare providers on a specific clotting condition being reported after COVID-19 vaccination. 2 April 2021. Available online at: https://www.health.gov.au/news/atagi-statement-healthcare-providers-specific-clotting-condition-reported-after-covid-19-vaccination (accessed April 2021).
24.    Royal Australian and New Zealand College of Obstetricians and Gynaecologists. COVID‑19 vaccination in pregnant and breastfeeding women. Updated 10 March 2021. available online at: https://ranzcog.edu.au/statements‑guidelines/covid‑19‑statement/covid‑19‑vaccination‑information (accessed April 2021).
25.    Hare H, Womersley K. Why were breastfeeding women in the UK denied the covid-19 vaccine? BMJ 2021; 372: n4. 
26.    Chervenak FA, McCullough LB, Bornstein E, et al. Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients. Am J Obstet Gynecol 2021; S0002-9378(21)00082-X. 
27.    Australasian Society of Clinical Immunology and Allergy (ASCIA). Allergy, immunodeficiency, autoimmunity and COVID-19 vaccination position statement. 26 March 2021. Available online at: https://www.allergy.org.au/hp/papers/ascia-hp-position-statement-covid-19-vaccination (accessed April 2021).
28.    Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021; 371: 1152-1153.
29.    Madhi SA, Baillie V, Cutland CL, et al; NGS-SA Group Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant.  N Engl J Med 2021 Mar 16. doi: 10.1056/NEJMoa2102214. [Online ahead of print.]
30.    Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum.  N Engl J Med 2021 Mar 8. doi: 10.1056/NEJMc2102017. [Online ahead of print.]
31.    Wang P, Wang M, Yu J, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization [preprint]. https://www.biorxiv.org/content/10.1101/2021.03.01.433466v1 (accessed April 2021).
32.    Hewings-Martin Y, Cohut M. New SARS-CoV-2 variants: how can vaccines be adapted? Medical News Today 15 March 2021. Available online at: https://www.medicalnewstoday.com/articles/new-sars-cov-2-variants-how-can-vaccines-be-adapted#Adapting-vaccines-to-match-variants (accessed April 2021).
33.    Australia Government. Australia’s COVID-19 vaccine national roll-out strategy. 2021. Available online at: https://www.health.gov.au/sites/default/files/documents/2021/01/covid-19-vaccination-australia-s-covid-19-vaccine-national-roll-out-strategy.pdf (accessed April 2021).